Plasma tau in Alzheimer disease.
Plasma tau in Alzheimer disease.
复制标题
DOI：
10.1212/wnl.0000000000003246
复制
发表时间：
2016-10-25
期刊：
影响因子：
9.9
通讯作者：
ADNI Investigators
中科院分区：
文献类型：
--
作者：
Mattsson N;Zetterberg H;Janelidze S;Insel PS;Andreasson U;Stomrud E;Palmqvist S;Baker D;Tan Hehir CA;Jeromin A;Hanlon D;Song L;Shaw LM;Trojanowski JQ;Weiner MW;Hansson O;Blennow K;ADNI Investigators
检测血浆tau蛋白在阿尔茨海默病（AD）中是否发生改变，以及是否与认知、AD病理学CSF生物标志物（包括β-淀粉样蛋白[Aβ]和tau蛋白）、脑萎缩和脑代谢变化相关。这是一项在来自阿尔茨海默病神经影像学倡议（ADNI）的前瞻性随访的AD患者（n = 179）、轻度认知障碍患者（n = 195）和认知健康对照（n = 189）以及横断面研究的AD患者（n = 61）、轻度认知障碍患者（n = 212）、和主观认知下降（n = 174）和对照（n = 274），来自瑞典隆德大学的生物标记物早期可靠地识别神经退行性疾病（BioFINDER）研究。共有1284名参与者参加了研究。测试了血浆tau与诊断、CSF生物标志物、MRI测量、18氟脱氧葡萄糖-PET和认知之间的关联。较高的血浆tau与AD痴呆、较高的CSF tau和较低的CSF Aβ42相关，但相关性较弱，并且ADNI和BioFINDER之间存在差异。ADNI的纵向分析显示，在随访期间，血浆tau蛋白与更差的认知、更多的萎缩和更多的低代谢之间存在显著相关性。血浆tau蛋白部分反映了AD病理学，但正常衰老和AD之间的重叠很大，特别是在没有痴呆的患者中。尽管存在组水平差异，但这些结果并不支持血浆tau作为个体人群的AD生物标志物。未来的研究可能会测试纵向血浆tau测量AD。
To test whether plasma tau is altered in Alzheimer disease (AD) and whether it is related to changes in cognition, CSF biomarkers of AD pathology (including β-amyloid [Aβ] and tau), brain atrophy, and brain metabolism. This was a study of plasma tau in prospectively followed patients with AD (n = 179), patients with mild cognitive impairment (n = 195), and cognitive healthy controls (n = 189) from the Alzheimer's Disease Neuroimaging Initiative (ADNI) and cross-sectionally studied patients with AD (n = 61), mild cognitive impairment (n = 212), and subjective cognitive decline (n = 174) and controls (n = 274) from the Biomarkers for Identifying Neurodegenerative Disorders Early and Reliably (BioFINDER) study at Lund University, Sweden. A total of 1284 participants were studied. Associations were tested between plasma tau and diagnosis, CSF biomarkers, MRI measures, 18fluorodeoxyglucose-PET, and cognition. Higher plasma tau was associated with AD dementia, higher CSF tau, and lower CSF Aβ42, but the correlations were weak and differed between ADNI and BioFINDER. Longitudinal analysis in ADNI showed significant associations between plasma tau and worse cognition, more atrophy, and more hypometabolism during follow-up. Plasma tau partly reflects AD pathology, but the overlap between normal aging and AD is large, especially in patients without dementia. Despite group-level differences, these results do not support plasma tau as an AD biomarker in individual people. Future studies may test longitudinal plasma tau measurements in AD.